What We Do
Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.
Our lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, we are conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including NASH, atopic dermatitis, immune and inflammatory hepatitis, and asthma. We are also developing Nanocyclo, a topical formulation of cyclosporine that has applicability in inflammatory skin diseases such as atopic dermatitis and psoriasis. This product is in late-stage preclinical testing.
Our subsidiaries Cytovia and Maxim Pharmaceuticals are developing additional assets.
|Immune Pharmaceuticals||Preclinical||Phase 1||Phase 2||Phase 3|
|Bullous Pemphigoid||Preclinical||Phase 1||Phase 2||Phase 3|
|IBD (Ulcerative Colitis)||Preclinical||Phase 1||Phase 2||Phase 3|
|Atopic Dermatitis / Psoriasis||Preclinical||Phase 1||Phase 2||Phase 3|
|NASH||Preclinical||Phase 1||Phase 2||Phase 3|
|Cytovia Immuno Oncology||Preclinical||Phase 1||Phase 2||Phase 3|
|Ceplene* Approved in EU||Preclinical||Phase 1||Phase 2||Phase 3|
|Crolibulin/Azixa||Preclinical||Phase 1||Phase 2||Phase 3|
|Nanomabs||Preclinical||Phase 1||Phase 2||Phase 3|
|Bispecific Antibodies||Preclinical||Phase 1||Phase 2||Phase 3|
|Maxim Pharmaceuticals||Preclinical||Phase 1||Phase 2||Phase 3|
|AmiKet||Preclinical||Phase 1||Phase 2||Phase 3|